PerkinElmer Health Sciences (Australia) offers Preimplantation Genetic Testing for Aneuploidy (PGT-A) services
In response to enquiries from IVF clinics, PerkinElmer Health Sciences (Aus) has established a Preimplantation Genetic Testing (PGT-A) service. Results can be achieved for aneuploidy screening using Next Generation Sequencing (NGS) with PG-Seq™.
The PGT-A service is offered to clinics that are not ready to bring testing in-house, but prefer to send their samples to a service provider. As the technology developer, PerkinElmer Health Sciences (Aus) has already accumulated many years of experience and competency with the technology it uses and its products are internationally competitive in their performance.
The PGT-A service is offered from the PerkinElmer Health Sciences (Aus) head office in Adelaide, Australia.
Contact us about our PGT-A service, including more specific information about costs, sample preparation requirements, turnaround time, and transportation.
PG-Seq™ and DOPlify® are for research use only and should not be used as a clinical diagnostic.
Please note: Clinics will need to enter into a Service Agreement with PerkinElmer Health Sciences (Aus) prior to sending samples.
How PGT-A services with PerkinElmer Health Sciences (Aus) fit into a clinical workflow
|Oocyte collection, fertilisation and culture||Other than recommending that fertilisation be achieved using Intracytoplasmic Sperm Injection (ICSI), there are no changes required for a clinic to offer PGT-A. Although it is possible to offer PGS on non-ICSI embryos, there is the potential for sperm contamination and the effect of this has not been validated by PerkinElmer Health Sciences (Aus).|
|Embryo biopsy||Any genetic test requires a small sample of cell(s) to be biopsied from the embryo. The stage and timing of the biopsy is at the sole discretion and responsibility of the clinic. After washing the embryo biopsy according to protocols provided by PerkinElmer Health Sciences (Aus), the cells are transferred to a tube, with the biopsy location marked on the outside of the tube. The tube is labelled and the cells are stored frozen or shipped immediately to PerkinElmer Health Sciences.|
|Freezing the embryo||Once the biopsy has been performed the embryos should be vitrified to allow sufficient time for transport and testing by PerkinElmer Health Sciences (Aus). Published data indicates that approximately 95% of vitrified embryos survive the freeze/thaw process¹ . Additionally, pregnancy rates are similar between fresh and frozen transfer cycles¹ .|
|Shipping the sample||The biopsy sample will be shipped frozen by courier to PerkinElmer Health Sciences (Aus), who are based in Adelaide, South Australia.|
|PGT-A test||In consultation and prior agreement with the clinic, PerkinElmer Health Sciences (Aus) will use the PG-Seq™ NGS workflow to assess the chromosomal complement of the biopsy sample.|
|PGT-A result||PerkinElmer Health Sciences (Aus) will return a report of the results of the testing. The format and content of the report will be agreed with the clinic prior to commencement of the service.|
|Embryo selection, thawing and transfer||In conjunction with the clinic’s own standard practice for embryo selection, such as morphology and morphokinetics, the clinic can use PGT-A results to consider which embryos are most suitable for IVF transfer.|
|Minimum Sample Size||A sample size of at least 24 for NGS analysis is required and this may initially (during the start-up phase) delay the timing for provision of results. Once the full 24 samples have been received, there is a 7 business day turn-around to us sending you the report. It is possible to process a smaller sample size but the cost per sample may be higher due to the cost of additional reagents required.|
¹ Single-embryo transfer of vitrified-warmed blastocysts yields equivalent live-birth rates and improved neonatal outcomes compared with fresh transfers, Roy TK, Bradley CK, Bowmans MC, McArthur SJ, 2014, Vol. 101 No 5, Fertility and Sterility
DOPlify® Whole Genome Amplification (WGA) Service
When starting with limited DNA template, whole genome amplification is used to generate sufficient DNA for downstream analysis in both research and clinical amplifications. PerkinElmer Health Sciences (Aus) sells a single cell WGA kit, DOPlify® and also offers a service for single cell, multi-cell and low template or copy number DNA sample amplification by highly experienced scientists in a specialised single cell facility.
WGA by PerkinElmer Health Sciences (Aus)'s DOPlify® kit generates a complex library and the WGA DNA generated is suitable for a wide range of applications but not limited to, Next Generation Sequencing, aCGH or primer-specific PCR and for the detection of copy number changes, segmental DNA changes, genome monitoring, SNP analysis and mitochondrial DNA mutation detection.
The success of all amplifications are assessed by PerkinElmer Health Sciences (Aus) using agarose gel electrophoresis as part of our quality control program.
The WGA service is offered from the PerkinElmer Health Sciences (Aus) head office in Adelaide, Australia.
Contact us about our WGA service, including more specific information about costs, sample preparation requirements, turnaround time, and transportation.
DOPlify® is for research use only and should not be used as a clinical diagnostic.